EDITORIAL

Revisit NIH biosafety guidelines

See allHide authors and affiliations

Science  18 Aug 2017:
Vol. 357, Issue 6352, pp. 627
DOI: 10.1126/science.aao6398

You are currently viewing the summary.

View Full Text

Summary

To celebrate the anniversary of an arcane federal guideline is a rare event. For an agency to use that moment to invite reflection on modifying policies is even rarer. Last month, the U.S. National Institutes of Health (NIH) did just that, with a workshop that marked the 40th anniversary of its Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules. The meeting was an inspiring start for charting future oversight of nonclinical applications.